Cytomegalovirus infection in transplant recipients by Azevedo, Luiz Sergio et al.
Cytomegalovirus infection in transplant recipients
Luiz Sergio Azevedon, Lı´gia Camera Pierrotti, Edson Abdala, Silvia Figueiredo Costa, Taˆnia Mara Vareja˜o Strabelli,
Silvia Vidal Campos, Je´ssica Fernandes Ramos, Acram Zahredine Abdul Latif, Nadia Litvinov,
Natalya Zaidan Maluf, Helio Hehl Caiaffa Filho, Claudio Sergio Pannuti, Marta Heloisa Lopes,
Vera Aparecida dos Santos, Camila da Cruz Gouveia Linardi, Maria Aparecida Shikanai Yasuda,
Heloisa Helena de Sousa Marques
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Committee for Infection in Immunosuppressed Patients,
Sa˜o Paulo/SP, Brazil.
Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to
transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in
seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or
invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic
stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and
in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus
seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used.
There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and
polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the
affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease.
Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a
subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of
viral replication before development of the disease and prescription of antiviral treatment to prevent the
appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less
frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in
cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2
to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.
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’ INTRODUCTION
Cytomegalovirus (CMV) is a ubiquitous herpes virus that
infects up to 60-100% of people in adulthood, and it is one of
the main agents involved in infectious complications after
transplantation. CMV, similarly to other herpes viruses,
establishes a latent infection after initial infection. In the
immunocompetent host, the initial infection is generally
asymptomatic but may present as an unspecified febrile, flu-
like or mononucleosis-like syndrome. In rare cases, the
infection presents as a systemic syndrome, affecting many
organs. Additionally, immunocompetent adults may present
a clinical syndrome later in life due to reactivation of latent
virus or due to new infection by another viral strain. The
disease caused by post-transplant CMV (PT-CMV) occurs
due to transmission from the transplanted organ, due to
reactivation of latent infection, or after a primary infection in
seronegative transplant patients (1–5).
CMV infection and disease can be defined as follows (6):
 latent infection – after the initial immune response, the
virus persists in a latent state, mainly in myeloid lineage
cells, and employs various mechanisms to evade the
immune system and to survive.
 active infection – the presence of viral replication, diagnosed
by growing the virus in vitro; by the discovery of intra-
cytoplasmic and intranuclear inclusions, which are character-
istics of the virus; by viral identification via tissue staining of
biopsy material; or by the discovery of evidence of viral repli-
cation detected by antigenemia assay or molecular methods.DOI: 10.6061/clinics/2015(07)09
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 disease – evidence of an infection with symptoms
attributed to it.
- viral syndrome –the presence of signs and symptoms of
disease and the confirmation of viral replication in the
peripheral blood (detected by antigenemia assay or
molecular techniques).
- invasive disease – the presence of specific symptoms in a
target organ and histological findings demonstrating the
cytopathic effect of the virus in tissue. In these instances,
there may or may not be evidence of viral replication in
the peripheral blood.
The most common clinical picture in the transplanted host
is a viral syndrome, characterized by fever and malaise as
well as leukopenia, thrombocytopenia and elevated liver
enzymes. These signs appear from the 3rd to 4th week, with a
peak from the 6th to 16th week, and become rare after the
6th month. Upper digestive tract symptoms, and mainly
pain, are common. Diarrhea, occasionally containing blood,
is more uncommon and is suggestive of colonic involvement.
Respiratory symptoms indicate more severe disease and may
require admission to an intensive care unit. Additionally,
clinical hepatitis, meningoencephalitis, pancreatitis and
myocarditis are rare. In contrast to what is found in HIV-
infected patients, chorioretinitis is very rare in transplanted
patients.
The occurrence of disease caused by CMV in transplanted
patients without prophylaxis varies according to the type of
transplantation, the serological match between donor and
recipient, the immunosuppressive drugs used (patients on
mTOR inhibitors have a very low incidence of CMV) and the
interference of additional illness risk factors. The incidence is
higher in patients undergoing lung or heart-lung transplantation
(an incidence of 50-75%) and in patients undergoing pancreas or
kidney-pancreas transplantation (an incidence of approximately
50%). The incidence of CMV is between 9 and 23% after heart
transplantation, between 22 and 29% after liver transplantation
and between 8 and 32% after kidney transplantation (7).
Moreover, 30% of patients undergoing allogeneic hematopoietic
stem cell transplantation (HSCT) and approximately 5% of
patients undergoing autologous HSCT develop CMV disease.
In solid organ transplantation (SOT), the greatest risk factor
for CMV disease is a serological mismatch between the donor
and the recipient (the recipient is CMV seronegative and the
donor is seropositive), (CMV D+/R-). Furthermore, CMV D
+/R+ transplantation and CMV D-/R+ transplantation are
considered to be of intermediate risk for the development of
disease, and CMV D-/R- transplantation is considered low
risk (o 5%) (8,9).
Additional risk factors include intense immunosupp-
ression (as determined based on the transplant center-
recommended immunosuppressant protocol and the drugs
and doses used), the use of lymphocyte-depleting antibodies
(such as antithymocyte globulin, or ATG), acute rejection,
advanced age in the donor and/or recipient, HLA mismatch,
other concurrent infections (such as with herpes virus 6 or 7)
and genetic polymorphisms (9–11). In HSCT, the risk of
disease is also higher both in seropositive recipients,
regardless of the donor’s serological status, and in the
presence of graft-versus-host disease (GVHD) (12).
In SOT, the disease caused by CMVoccurs mainly between
30 and 90 days after transplantation and is rare after
180 days. Onset may be delayed when antiviral prophylaxis
is used. However, the disease may occasionally develop at
other times (13–15).
The deleterious effects of CMV in transplant recipients
result from the direct cytopathic effect of the virus on various
organs and systems, mainly causing pneumonia, gastro-
intestinal tract disease, hepatitis, encephalitis, and retinitis.
CMV disease has a major impact on morbidity and
mortality in transplant patients. Moreover, the disease
contributes greatly to increased use of diagnostic and
therapeutic resources and to the overall cost of transplanta-
tion. CMV infection may also have indirect effects that
influence graft dysfunction, accelerate coronary artery
atherosclerosis and increase the risk of other opportunistic
infections (16–18).
A proposed definition of the different clinical syndromes is
presented in Table 1 (19–22).
’ DIAGNOSIS
Diagnosis of the infection caused by CMV has evolved
considerably in recent years. There are two methods used to
diagnose active CMV infection: the pp65 antigenemia assay
and polymerase chain reaction (PCR), which can be used for
the early detection of CMV viral replication. However, there
is a tendency to replace the antigenemia assay with
molecular methods, particularly in monitoring CMV viral
replication after transplantation (23–27).
Traditional diagnostic methods such as culture on human
fibroblasts have no practical use because they can take up to
two weeks to show a positive result, and even then, they are
not indicative of an active infection. Meanwhile, tests using
the interferon-gamma release assay (IGRA), such as Quanti-
FERON and ELISpot, do not yet have a defined role in
diagnosis and monitoring.
Serological diagnosis
Serology is useful in determining the serological status of
the donor and recipient prior to transplantation to thereby
define the post-transplant risk, given that CMV-negative
recipients receiving an organ from CMV-positive donors
develop more frequent and more aggressive disease. After
transplantation, however, the value of serology is limited,
and serology has no value for the diagnosis of active disease
or infection (28).
Serological diagnosis of CMV infection can be accom-
plished by dosing the IgM and IgG antibodies. The first
antibody to appear is IgM, which may be present in the
patient’s serum for a long period of time after the infection.
Moreover, this antibody may reappear after reinfection,
including infection by different strains of the virus, demon-
strating that IgM positivity is not diagnostic of a primary or
recent infection with CMV. The IgG antibody appears in the
blood after 6 to 8 weeks of infection and can persist
indefinitely, although with fluctuation in its levels. For this
reason, this antibody is used to define the serological
relationship between the donor and the recipient (D/R). If
the donor’s serology is doubtful or inconclusive, it should be
considered positive. If the serology is negative in the initial
pre-transplant evaluation and there is a long delay until the
transplant, the serology should be repeated, especially if the
patient received a blood transfusion in the meantime. It is
important to remember that the presence of IgG antibody
does not protect the individual from reactivation of a latent
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viral infection or from a new infection with a different strain
of the virus.
Serology in immunocompromised patients can be difficult
to interpret due to the patients’ impaired humoral responses.
Moreover, they can present circulating IgG from transfusions
or from treatments with immunoglobulin.
Antigenemia assay
The CMV antigenemia test is a rapid method for the
detection of CMV phagocytized by neutrophils in the
peripheral blood. In particular, monoclonal antibodies to
CMV pp65 protein are used as an early and specific marker
of active infection. The blood sample should be collected
with anticoagulant, and the results are expressed as the
number of polymorphonuclear cells infected in relation to
the total number of polymorphonuclear cells counted. The
antigenemia assay is comparable to quantitative PCR in that
it is a highly specific method for CMV detection and has
predictive value for the disease severity, which is related to
the number of cells detected. However, serious infections
may exist with a low number of positive cells or even in their
absence. In general, the number of positive cells has been
used as an indicator of when to start preemptive treatment.
Although positive cells represent viral replication, a cut-off
number of cells specific to each transplant center should be
established for disease diagnosis. From one to ten or more
cells are accepted as a cut-off number for SOT, and one or
two cells are accepted for HSCT. The antigenemia assay is
also used to evaluate the response to antiviral treatment, and
its disappearance from the bloodstream is considered as a
marker of therapeutic efficacy (29,30).
The advantages of the antigenemia assay are that it can be
performed soon after blood collection and has a short
processing time (approximately 6 hours), enabling early
diagnosis of the infection, and that it does not require
sophisticated and expensive equipment and can be per-
formed in medium-capacity laboratories. The disadvantages
include the following: the test needs to be conducted
immediately after the collection of blood samples (no more
than 6 hours later); its quantification is subjective and
dependent on the expertise of the person who performs the
test; it is not an uniformly standardized method, with
extensive variability in its practice, which can compromise
reproduction of the method in different laboratories; and it
can only be applied if there is an adequate number of
circulating cells, which limits its use in patients with
leukopenia (the neutrophil count must be greater than
200/mm3), particularly in HSCT recipients. The result may
specifically be doubtful in patients with a neutrophil count
below 1,000/mm3.
Quantitative PCR
Viral load quantification in CMV by quantitative PCR is
the main alternative option for the diagnosis of viral
replication and for decision making regarding preemptive
treatment and monitoring the response to treatment (28,31).
This test is carried out using the real-time PCR (RT-PCR)
technique, which provides better accuracy, a faster response
time, higher efficiency and a lower risk of contamination
compared with conventional PCR. Quantification of the viral
load can be conducted using plasma, whole blood or
cerebrospinal fluid. In addition to the test’s high sensitivity,
limited concordance has been observed between bronchoal-
veolar lavage positivity by PCR and systemic infection (32).
CMV DNA is generally detected earlier and in greater
amounts in whole blood compared with plasma. However,
there is a poor correlation of the quantitative values for
the viral load test between laboratories, partly due to the
Table 1 - Definitions: CMV syndrome and disease affecting different organs (19–22).
Disease Presumed diagnosis Confirmation
CMV syndrome The presence of one or more of these signs: fever
4 2 days, malaise, leukopenia, 4 5% atypical
lymphocytes, thrombocytopenia, and increased
aminotransferases (4 2-fold, except in liver
transplantation) plus evidence of active CMV infection
Clinical and laboratory evidence of CMV infection
without confirmation of other etiology
Pneumonia The presence of signs and symptoms of pneumonia
(fever, cough, dyspnea, hypoxemia, X-ray changes)
plus evidence of CMV infection in the blood and/or
bronchoalveolar lavage
Lung disease manifestations plus the presence of
CMV in lung tissue based on immunohistochemistry
with or without evidence of active CMV infection in
the blood or bronchoalveolar lavage
Gastrointestinal disease
(esophagitis, gastritis,
enterocolitis, colitis)
The presence of signs and symptoms of
gastrointestinal compromise plus endoscopic signs of
mucosal lesions and evidence of active CMV infection
in the blood
Gastrointestinal manifestations plus the detection of
CMV in gastrointestinal tissues by
immunohistochemistry
Hepatitis An increase in liver enzymes and bilirubin levels
(4 2-fold) in the absence of other known causes plus
evidence of CMV in the blood
The presence of increased liver enzymes and bilirubin
levels plus the presence of CMV in liver tissue, as
determined by immunohistochemistry; note that the
presence of hepatitis and CMV in the blood, without
histological confirmation of CMV in liver tissue, does
not allow for the diagnosis of hepatic invasive disease
Central nervous system
disease
Neurological signs and symptoms in the absence of
other known causes plus evidence of CMV (as detected
by RT-PCR) in the cerebrospinal fluid
Neurological signs and symptoms plus evidence
of CMV in brain tissue, as detected by
immunohistochemistry
Retinitis Not applicable Typical CMV lesions on the retina, as confirmed by an
ophthalmologist
Invasive disease in other
organs (e.g., nephritis,
myocarditis, pancreatitis)
The presence of organ dysfunction in the absence of
other known causes plus evidence of CMV in the blood
The presence of organ dysfunction plus the presence
of CMV in the target organ tissue, as detected by
immunohistochemistry
Evidence of active CMV in the blood: positivity of antigenemia or RT-PCR testing.
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lack of an international reference standard and partly due
to variations in the assay. This variation prevents the
creation of widely applicable cut-off points for clinical deci-
sion making, especially for preemptive treatment strategies
(31,33).
Studies have shown that higher viral load values correlate
with an increased risk of developing the disease (34). Certain
publications reported the same efficacy for preemptive
treatment and universal prophylaxis in randomized clinical
trials performed with kidney transplant recipients using an
intervention cut-off point of 42,000 copies/mL of whole
blood (35,36). The evolution of the viral load over time might
be more important for predicting disease development than
any of the absolute viral load values are. The detection limit
varies among different viral load tests, and a lower detection
limit of more than 1,000 copies/mL (using whole blood or
plasma) may be insufficient to detect the disease because
certain severely ill patients may present very low viral loads.
However, a very sensitive test (detection limito10 copies/mL)
can detect the latent virus, especially if whole blood is used,
which limits the clinical usefulness of an extremely sensitive
test (28). The results of this test should be available between
24 and 48 hours and should be reported as the number of
copies or transformed into logarithms or I.U.
Comparison between RT-PCR and
antigenemia assay
Both the antigenemia and the viral load tests for CMV
DNA have clinical utility, and in general, there is good
correlation, although not uniform, between the CMV antigen
levels and viral load values. However, the antigenemia assay
has low sensitivity in the detection of CMV reactivation in
patients undergoing HSCTwho develop viremia before bone
marrow grafting and in transplant patients who develop
localized disease, such as CMV disease of the gastrointestinal
tract. In this case, RT-PCR is more useful (28,37).
Quantitative PCR seems to be superior, more sensitive and
faster than the antigenemia assay for the diagnosis of CMV
infection and for the detection of CMV reactivation in
transplant patients (38–43). A discrepancy between the
results of antigenemia and quantitative PCR testing gener-
ally occurs when viremia is low, with an average of 0.5
positive cells per field in the antigenemia assay or less than
1,000 DNA copies/mL of plasma in quantitative PCR (39).
The decision regarding which test to use depends on many
factors, such as the available resources and technical
expertise, the patient population, the time requirement, the
sample volume and the cost.
Viral resistance
A controversial issue in the management of CMV is the
development of viral resistance to the drug used to treat
patients. Additionally, few studies have evaluated the
development of antiviral resistance in transplant patients
(44–46). Sequencing that detects the mutations that cause
resistance is considered as the gold standard. For example,
ganciclovir-resistant CMV is usually associated with muta-
tions in UL97 (a protein kinase) and UL54 (a DNA polymerase)
(47–50).
Histological diagnosis
The analysis of a biopsy of the affected tissue is useful
in the diagnosis of invasive disease, both based on the
presence of intracellular viral inclusion and based on the
detection of CMV antigens by immunohistochemistry or
DNA hybridization, together with an inflammatory
response. Due to the impossibility of histological analysis,
involvement of the central nervous system can be deter-
mined based on the presence of CMV in the cerebrospinal
fluid, as detected by RT-PCR.
Prevention and treatment
The prevention of CMV infection aims to reduce the
incidence of CMV disease and the indirect effects associated
with viral replication (20,28,51). The high-risk groups include
D+/R-, those receiving depleting antibodies (ATG) and lung
transplant recipients. In contrast, D-/R- patients have a low
risk of developing CMV. Importantly, blood transfusions
from CMV+ donors may represent a risk for CMV- patients,
who should therefore receive either transfusions from CMV-
donors or leukocyte-depleted transfusions.
CMV can be prevented in two ways: by prophylaxis and
by preemptive treatment. Both options are effective for
preventing CMV disease. There is no consensus on which is
the best option, but there is a trend favoring prophylaxis in
D+/R- patients (52).
CMV-specific T cells are crucial for controlling post-
transplant CMV replication (53–56). The possible impact of
CMV-specific immune response monitoring on the prophy-
laxis and management of CMV has been considered in HSCT
and in SOT and requires validation (57–59).
Transplant recipients receiving mTOR inhibitor treatment
have significantly lower rates of CMV disease (60); whether
this should alter the prevention strategy requires further
study.
No specific vaccine against CMV is available for clinical
use.
Prophylaxis
Prophylaxis is the administration of antiviral drugs to all
patients (universal prophylaxis) or to a subgroup of patients
at higher risk of viral replication (specific prophylaxis) for a
predetermined period of time in cases with an increased
occurrence of viral replication after transplantation. This
approach should be initiated as early as possible. A delayed
onset of infection may occur after the discontinuation of
prophylaxis, and there is evidence of a lower CMV incidence
after prophylaxis suspension following a longer period of
drug use (61). Although no consensus has been reached
regarding the period of antiviral use, prophylaxis is usually
conducted for 3 to 6 months post-transplantation. There is
also a tendency to recommend monitoring of the intensity of
CMV viral replication after the end of the prophylaxis period
during the first year post-transplant. The antivirals used are
ganciclovir (intravenous and/or oral) and valganciclovir.
Alternatively, oral valacyclovir may be used.
As a rule, prophylaxis is indicated in the following cases:
transplantation in CMV D+/R- and transplantation with the
use of induction or with treatment of rejection with ATG.
Antiviral drug treatment should begin immediately after
transplantation or after the use of ATG. The medication
duration is usually three months, although several authors
advocate a longer prophylaxis period (28,31,61).
The arguments in favor of prophylaxis are that the use of
antivirals would prevent both viral replication and disease
and would therefore reduce the indirect effects of viral
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replication. Moreover, with this approach, laboratory mon-
itoring of viral replication would not be necessary.
The arguments against prophylaxis are the cost and side
effects of antiviral drugs; the probability of occurrence of the
disease once the prophylaxis ends; and its association with
greater delays in clinical suspicion, diagnosis and treatment,
leading to the possibility of greater morbidity and mortality.
In addition, those who might require treatment as well as
those who might not are medicated indiscriminately.
Another aspect to consider is the increasing incidence of
viral resistance in patients undergoing SOT who receive
antiviral prophylaxis. The gene related to ganciclovir
resistance can be sequenced (UL97) and detected within 24
to 48 hours in certain research laboratories, and the same is
expected for the gene UL54, encoding a polymerase, which
contains mutations conferring resistance to foscarnet and
cidofovir (62,63).
Another possible argument against prophylaxis is the lack
of immune stimulation due to the absence of early viral
replication, leading to the absence of a specific immune
response to CMV (64).
Preemptive treatment
The goal of preemptive treatment is the early diagnosis of
viral replication, before the development of the disease. This
diagnosis is performed through regular laboratory monitor-
ing for the detection of viral replication. When viral
replication is above a predetermined limit, antiviral treat-
ment is indicated to prevent the appearance of clinical
disease (hence the term ‘‘preemptive,’’ also called ‘‘pre-
symptomatic’’). There is no default value for the indication of
preemptive treatment, so each transplant center must
establish this limit. However, from a theoretical point of
view, any level of viral replication should be an indication for
preemptive treatment to stop the indirect effects of CMV. The
main limitation of this approach is the only partial preven-
tion of the indirect effects of viral replication, including
effects on graft and patient survival (65–67).
The advantages of preemptive treatment include a lower
cost and no incidence of drug side effects because an antiviral
drug is not used and the theoretical possibility of stimulating
the development and maintenance of a CMV-specific immune
response due to viral replication in the absence of antiviral
drugs. Furthermore, preemptive treatment avoids the use of
drugs in a patient who effectively does not need them.
However, by allowing viral replication, indirect effects may be
triggered. The disadvantages include the following: blood
collection logistics; test costs; the need for laboratory support
to obtain the results of viral replication monitoring within the
time frame required for immediate initiation of preemptive
treatment, when indicated; and the risk of recurrent episodes
of replication, with indications for more than one preemptive
treatment, especially in patients with increased immunosup-
pression, lung transplantation or D+/R- CMV status. Blood
samples should be collected frequently (ideally weekly) for a
long period of time (3 to 6 months). However, this approach
limits patient adherence and may cause preemptive treatment
failure.
Comparison between prophylaxis and
preemptive treatment
There is no consensus on the best method. Preemptive
therapy depends on the logistic routine of CMV monitoring,
the availability of accurate assays, efficient access to results,
and rapid initiation of therapy after positive replications. To
induce a very rapid increase in viral load in high-risk cases,
such as patients with D+/R- status, lung transplant
patients, and those on potent immunosuppression, prophy-
laxis is probably safer and is more highly recommended than
preemptive therapy (31,51).
There have been few comparative randomized studies.
Khoury et al. (35) found similar data for the prevention of
CMV disease in relation to preemptive prophylaxis com-
pared with treatment, 5 out of 98 patients (5%) developed
disease: 4 (8%) in the prophylactic group and 1 (2%) in the
preemptive group. As expected, there was a higher rate of
viremia with preemptive therapy (59% vs. 29%). Late
emergence of viremia (4100 days after transplantation)
occurred in 24% of patients undergoing prophylaxis,
compared with 0% of the patients undergoing preemptive
treatment. In another study, Kliem et al. (66) found a
significant reduction in CMV disease in 12 months (17% in
the prophylaxis group vs. 50% in the preemptive treatment
group). Patients on prophylaxis developed invasive infec-
tions later (135 vs. 39 post-transplant days ). There was no
significant difference in renal function in the short term.
However, the incidence of graft loss in the 4th year post-
transplant was higher in patients on preemptive treatment
(78% vs. 92%). Witzke et al. (68) found respective viremia
rates of 38.7% vs. 11% and invasive CMV disease rates of
19.2% vs. 4.4% in the preemptive and prophylaxis groups.
Spinner et al. (69) found no long-term (4 years) difference in
relation to acute rejection, kidney loss or death in patients on
prophylaxis or under preemptive treatment. Reischig et al.
(36) found a similar frequency of CMV disease with
preemptive treatment and prophylaxis (6% vs. 9%), and the
emergence of viremia occurred at 37 vs. 187 days post-
transplant. Acute rejection was more frequent in the
preemptive group (36% vs. 15%). In two studies, the
comparative cost was assessed and was similar in the two
schemes, considering the cost of the antiviral drugs and of
monitoring by PCR (35,58). Notably, the costs of antigenemia
testing are lower than those of RT-PCR.
There is also a hybrid strategy used by certain transplant
centers in D+/R- cases: prophylaxis followed by preemp-
tive treatment to prevent the emergence of late invasive
disease (28).
’ ANTIVIRALS
The use of antivirals should be based on standardized
doses with respective correction algorithms for the level of
renal function (Tables 2 and 3).
Prophylaxis
According to current guidelines (28,70), the prophylaxis
options include intravenous ganciclovir, oral valganciclovir,
and high doses of oral valacyclovir in renal transplant
recipients. Oral ganciclovir has been used, although several
studies have showed less optimal outcomes.
Although valganciclovir is the best drug for prophylaxis
because it is effective and available in oral form, its high cost
limits its use, and it is frequently not available. Therefore,
intravenous ganciclovir may be considered, as it is cheaper
and widely available, despite the need for intravenous use.
This drug has even been used as a three-times-weekly
regimen (71). Valacyclovir, although less effective, is also
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available in oral form and may be an alternative to no drug
at all (72, 73).
Regarding the prevention of CMV disease, treatment with
oral CMX001 at a dose of 100 mg twice weekly reduced the
incidence of CMV events in HSCT recipients, and diarrhea
was a common adverse event at a dose of 200 mg given twice
weekly (74).
Treatment
Treatment is always indicated in viral syndrome, in the
presence of CMV disease (evidence of CMV infection with
signs and symptoms of the disease) and when tissue and
organ damage are documented by histological and immu-
nohistochemical changes. During surveillance for preemp-
tive treatment, antiviral drugs should be started as soon as
the presence of a replicating virus is detected by either
antigenemia or RT-PCR testing.
The gold-standard drug for treatment is intravenous
ganciclovir. There is a limited evidence that oral valganci-
clovir is also effective (75). Therefore, intravenous ganciclovir
is the choice for severe infection, but for mild to moderate
infection it is possible to use valganciclovir treatment.
Acyclovir and valacyclovir are not indicated for treatment.
Concomitant use of mycophenolate, azathioprine, mTOR
inhibitors or sulfamethoxazole-trimethoprim may favor
leukopenia. Modifications of established therapeutic regi-
mens should also be avoided, except in cases of marked
leukopenia. In such cases, filgrastim is indicated.
The recommended length of treatment is determined by
the weekly monitoring of CMV viral loads; the treatment
should be continuous until viral eradication is achieved in
one or two assays after a minimum of two weeks. The use of
immune-based assays could have potential clinical utility in
guiding treatment length and identifying patients with
negative assay results at the end of treatment, who might
benefit from secondary prophylaxis (24,28,59).
Risk factors that suggest a need for prolonged treatment
include high viremia at the beginning of treatment and CMV
recurrence. Risk factors for resistance include prolonged
antiviral drug exposure under ongoing active viral replica-
tion, high levels of immunosuppressive therapy, and
inadequate antiviral doses (28). Drug resistance should be
suspected with the persistence of or an increase in viral load
in the presence of CMV prophylaxis as well as persistent
viral replication and/or clinical progression after two to
three weeks of treatment (28,73).
Foscarnet is an alternative choice for ganciclovir-resistant
CMV, although frequent side effects, and mainly nephro-
toxicity, limit its use (44,76).
No consensus has been reached on the use of secondary
prophylaxis after completion of treatment of acute infection.
However, certain authors recommend this approach for high-
risk patients (28).
’ SPECIAL SITUATIONS
Hematopoietic stem cell transplantation
CMV reactivation may occur in 30% of HSCT patients and
in up to 70% of high-risk patients, such as those with positive
serology who received a transplant from a negative donor
(77). In total, 30% of patients undergoing allogeneic
transplantation and approximately 5% of those undergoing
autologous transplantation develop CMV disease. In HSCT,
reactivation usually occurs within the first 30 days after
transplantation and in those who develop GVHD. CMV can
be reactivated throughout the entire period of immunosup-
pressive drug use (78,79). Mortality in patients who develop
pneumonia or disseminated disease may reach 90%. CMV
reactivation can also present as an engraftment delay.
Table 3 - Antiviral drug doses recommended for treatment according to the glomerular filtration rate, which is
estimated based on creatinine clearance
Drug Creatinine clearance
460 mL/min 40–60 mL/min 25–40 mL/min 10–25 mL/min o10 mL/min dialysis
intravenous ganciclovir 5 mg/kg twice per day 2.5 mg/kg twice per day 2.5 mg/kg/day 1.25 mg/kg/day 1.25 mg/kg after dialysis
oral valganciclovir* 900 mg twice per day 450 mg twice per day 450 mg/day 450 mg every other day not recommended**
* 1 tablet = 450 mg
** intravenous ganciclovir is recommended
Note: valacyclovir and valganciclovir should be given with meals
Table 2 - Antiviral drug doses recommended for prophylaxis according to the glomerular filtration rate, which is
estimated based on creatinine clearance
Drug Creatinine clearance
460 mL/min 40–60 mL/min 25–40 mL/min 10–25 mL/min o10 mL/min dialysis
Intravenous ganciclovir 5 mg/kg/day 2.5 mg/kg/day 1.25 mg/kg/day 1.5-1.25 mg/kg/day three
times per week
1.5-1.25 mg/kg/day
after dialysis
Oral valacyclovir* 2 g four times
per day
2 g three times
per day
1.5 g three times
per day
1.5 g twice per day 1.5 g/day
Oral valganciclovir** 900 mg/day*** 450 mg/day 450 mg 48/48 h 450 mg 2 times per week not recommended****
* 1 tablet = 500 mg
**1 tablet = 450 mg
*** certain authors recommend 450 mg/day 2
**** intravenous ganciclovir is recommended
Note: valacyclovir and valganciclovir should be given with meals
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Preemptive treatment reduces the incidence of the disease
and the mortality of this agent in this patient population.
Ljungman et al. (79) showed that the incidence of CMV
disease in patients who received preemptive treatment was
1.8% at 100 days after transplantation and 6.3% at one year
after transplantation.
CMV-negative patients with CMV-negative donors should
receive only leukocyte-depleted blood products or transfu-
sions from CMV-negative donors. Preemptive treatment is
indicated both in autologous and in allogeneic transplanta-
tion. Treatment is started during conditioning and is given
up the 100th post-transplant day. Two weekly surveys
(antigenemia or RT-PCR testing) are also performed. In
pediatric patients with autologous transplantation, treatment
is started upon engraftment and is given until the 60th post-
transplant day, with weekly surveys (antigenemia or RT-PCR
testing). With allogeneic transplants, treatment begins on the
10th day after transplantation and continues until the 100th
day. Treatment is also given to patients who develop GVHD.
A comparison between the viral load test and the anti-
genemia test for the recommendation of preemptive treat-
ment in HSCT recipients showed that the use of viral load
testing significantly reduced the number of patients who
required preemptive treatment, with no increase in CMV
disease. Comparable data are not available for SOT.
Lung transplantation
The incidence of CMV infection and disease is higher in lung
transplantation recipients than in other SOT recipients, with an
incidence of 54% to 92% in patients without CMV prophylaxis
(80). In addition to direct morbidity and mortality, CMV
infection has been associated with episodes of acute cellular
rejection as well as with chronic allograft dysfunction, which is
the main limiting factor for the long-term success of lung
transplantation (81). Although no study has compared prophy-
laxis and preemptive therapy in lung transplantation, the high
frequency of these complications post-transplant makes the use
of CMV prophylaxis essential in lung transplant recipients.
In 2005, an advisory committee of CMV experts established
the following recommendations for lung transplant centers (82):
All lung transplant recipients must receive CMV prophy-
laxis, as follows:
1-Prophylaxis should be performed with valganciclovir
900 mg/day (dose adjusted for the glomerular filtration rate)
for at least 100 days;
2-Prolonged prophylaxis (over 180 days) may be consid-
ered by all centers, considering a reduction in the incidence
of infection/disease and the indirect effects of CMV;
3-Prophylaxis should combine antivirals and CMV immu-
noglobulin, which is effective for the prevention of CMV
infection/disease and which must be considered for high-
risk groups (D+/R- patients and patients using ATG);
4-During the first 6 months after transplantation, including
the period of prophylaxis, monitoring of CMV viremia must
be performed every 2 weeks (by RT-PCR or pp65 anti-
genemia testing) in accordance with the local protocols, and
after 6 months, monitoring should be performed monthly
until the end of the first year after the transplant.
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